MNK - Mallinckrodt plc

NYSE - NYSE Delayed Price. Currency in USD
9.61
+0.51 (+5.60%)
At close: 4:02PM EDT

9.65 +0.04 (0.42%)
After hours: 7:26PM EDT

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close9.10
Open9.10
Bid9.30 x 900
Ask9.65 x 1800
Day's Range8.83 - 9.73
52 Week Range8.45 - 36.65
Volume3,681,241
Avg. Volume2,595,393
Market Cap805.451M
Beta (3Y Monthly)2.51
PE Ratio (TTM)N/A
EPS (TTM)-41.21
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.54
  • Cramer Remix: Why Chipotle's downgrade is misguided
    CNBCyesterday

    Cramer Remix: Why Chipotle's downgrade is misguided

    Jim Cramer explains why worries at the restaurant chain may be off-base.

  • This May Hurt a Little (Or a Lot) as Opioids Haunt Pharma Bonds
    Bloombergyesterday

    This May Hurt a Little (Or a Lot) as Opioids Haunt Pharma Bonds

    The investors are taking advantage of sliding prices for notes issued by companies such as Endo International Plc, Mallinckrodt Plc and Teva Pharmaceutical Industries Ltd., which face allegations that they’ve fueled the opioid epidemic, and that they’ve engaged in price-fixing of generic drugs. Mallinckrodt is also in a legal battle with the U.S. over a plan to slash reimbursements on Acthar, the company’s star drug.

  • Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS
    Zacks2 days ago

    Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS

    Mallinckrodt (MNK) declines after filing suit against HHS and CMS for the protection of Medicaid patient access to Acthar.

  • PR Newswire2 days ago

    Wolf Popper LLP Announces Investigation on Behalf of Investors in Mallinckrodt plc

    NEW YORK , May 22, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Mallinckrodt plc (NYSE: MNK) common stock from April 13, 2016 through ...

  • Benzinga2 days ago

    Mallinckrodt Slumps After Filing Acthar Lawsuit, But BMO Says It Can Take The Hit

    Mallinckrodt PLC (NYSE: MNK) announced Tuesday that it filed a lawsuit against the Department of Health and Human Services and Centers for Medicare and Medicaid Services, challenging the federal government's decision to have the company change the base date average manufacturer price used to calculate Medicaid drug rebates for Acthar gel. The news of the lawsuit is disappointing, as it could potentially eliminate Acthar's Medicaid sales, Nachman said in a Tuesday note.

  • Barrons.com2 days ago

    Mallinckrodt Stock Could Take Another Plunge, Analyst Says

    The drugmaker is facing headwinds from opioid lawsuits and a decision by the federal government to cut reimbursements for a key product.

  • Mallinckrodt shares crater after drug maker files suit to protect Medicaid patient access to Acthar
    MarketWatch3 days ago

    Mallinckrodt shares crater after drug maker files suit to protect Medicaid patient access to Acthar

    Mallinckrodt PLC shares tumbles after the drug company says it has filed suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services to protect Medicaid patient access to its Acthar gel.

  • Business Wire3 days ago

    LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims on Behalf of Investors

    Mallinckrodt plc shares have declined by nearly 38% in 2019 due to issues with health regulators and accusations of kickbacks. Gibbs Law Group is investigating a Mallinckrodt class action lawsuit on behalf of investors who lost money in Mallinckrodt plc (MNK) stock. To speak privately with an attorney regarding this class action lawsuit investigation, call (800) 808-5294 or click here.

  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of MNK earnings conference call or presentation 7-May-19 12:30pm GMT

    Q1 2019 Mallinckrodt Plc Earnings Call

  • Moody's3 days ago

    Mallinckrodt International Finance SA -- Moody's downgrades Mallinckrodt's CFR to B2; outlook remains negative

    Moody's Investors Service ("Moody's") downgraded Mallinckrodt International Finance SA's ("Mallinckrodt") Corporate Family Rating ("CFR") to B2 from B1 and Probability of Default Rating ("PDR") to B2-PD from B1-PD. Moody's downgraded the senior secured revolver and term loans to Ba3 from Ba2, the guaranteed senior unsecured notes to B3 from B2, and the unguaranteed senior unsecured notes to Caa1 from B3. The Speculative Grade Liquidity Rating was affirmed at SGL-2.

  • Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today
    Motley Fool3 days ago

    Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today

    Tough conditions for these companies left them out of the day's rally.

  • PR Newswire3 days ago

    Mallinckrodt Announces Election of Carlos V. Paya, M.D., Ph.D. to its Board of Directors

    STAINES-UPON-THAMES, United Kingdom, May 21, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty pharmaceutical company, announced today the election of Carlos V. Paya, M.D., Ph.D. to the company's Board of Directors. Dr. Paya has 30 years of branded pharmaceutical industry, science and medical practice experience, and joins the Mallinckrodt Board effective tomorrow, May 22, 2019.

  • Benzinga3 days ago

    Mallinckrodt Shares Fall 25%: What You Need To Know

    Biopharmaceutical company Mallinckrodt plc (NYSE: MNK )'s shares lost about 25 percent of their value Tuesday following news that the company filed suit against the Department Of Health And Human Services ...

  • TheStreet.com3 days ago

    Mallinckrodt Is Circling the Drain - Do Not Go Down With It

    In this daily bar chart of MNK, below, we can see a lot of bearish signals. The daily On-Balance-Volume (OBV) line has been declining along with price since August, telling us that sellers of MNK have been more aggressive with heavier volume being transacted on days when the stock has closed lower. In the bottom panel we fail to find a bullish divergence from the momentum study so no early warning of a low.

  • GlobeNewswire3 days ago

    Mallinckrodt Investigated by Block & Leviton LLP For Violations of Federal Securities Laws

    BOSTON, May 21, 2019 -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating whether Mallinckrodt PLC (NYSE: MNK) and certain of.

  • Bloomberg3 days ago

    Mallinckrodt Plunge to Record Low Is a Win for Short Sellers

    Mallinckrodt is looking to reverse a decision that it says would “substantially eliminate” the 10% of Acthar Gel sales that come from Medicaid, the company said in a statement on Tuesday. The stock’s most bearish analyst, Berenberg’s Patrick Trucchio, slashed his price target in half to $5 and reiterated his sell-equivalent rating on Tuesday. Mallinckrodt said it has flagged potential risks tied to government rebate programs in annual filings and disclosed this specific matter when it determined it to be necessary to do so.

  • TheStreet.com3 days ago

    Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

    The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.

  • Why Mallinckrodt Stock Is Tanking Today
    Motley Fool3 days ago

    Why Mallinckrodt Stock Is Tanking Today

    The company filed a lawsuit to stop a federal decision that could be very bad news for its top drug.

  • MarketWatch4 days ago

    UPDATE: Mallinckrodt stock slides 10% premarket after it files suit over Medicaid patient access to Acthar gel

    Mallinckrodt Plc shares fell 10% in premarket trade Tuesday after the drug company said it has filed suit against the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to protect Medicaid patient access to its Acthar gel, a treatment a range of illnesses including MS and lupus. The suit "seeks to hold unlawful and set aside the Agency's recent unjustified decision to require that Mallinckrodt change the base date average manufacturer price (AMP) used to calculate Medicaid drug rebates for Acthar(R) Gel (repository corticotropin injection)," the company said in a statement. The CMS decision reverses without explanation a 2012 approval of the calculation of Medicaid rebates for the gel, said Mallinckrodt. "We are disappointed with the action taken by CMS. "With our repeated attempts to engage both HHS and CMS in productive discussions ultimately rebuffed, we find ourselves with no other choice than to vigorously defend our position, through the courts, that Medicaid patients should have access to this important therapy," said Mark Casey, general counsel at Mallinckrodt. The move would eliminate Medicaid sales of the gel and undermine the company's effort to build on its existing investment of more than $500 million to modernize the gel. It would also limit the company's ability to continue to invest in R&D for a pipeline that includes such diseases as ALS, Duchenne muscular dystrophy and others. The company said the issue could have an up to $600 million impact. Shares are down 18% in the last 12 months, while the S&P 500 has gained 3.9%.

  • PR Newswire4 days ago

    Mallinckrodt Files Suit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) to Protect Medicaid Patient Access to Acthar® Gel

    STAINES-UPON-THAMES, United Kingdom, May 21, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, today confirmed its subsidiary, Mallinckrodt ARD LLC (Mallinckrodt), has filed suit in federal district court against the HHS and CMS (or the Agency). The action seeks to hold unlawful and set aside the Agency's recent unjustified decision to require that Mallinckrodt change the base date average manufacturer price (AMP) used to calculate Medicaid drug rebates for Acthar® Gel (repository corticotropin injection).

  • Coatue Management’s Latest Moves
    Insider Monkey8 days ago

    Coatue Management’s Latest Moves

    Coatue Management is a New York City-based hedge fund that was launched back in 1999 by Philippe Laffont. The fund provides additional office in Menlo Park, California. At the end of 2016, it held around $10.25 billion in assets under management. Coatue Management looks for the stocks to invest in from the technology sector, utilizing […]

  • Mallinckrodt Ends Enrollment in Phase III for Terlipressin
    Zacks9 days ago

    Mallinckrodt Ends Enrollment in Phase III for Terlipressin

    Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Fool10 days ago

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Cramer: Mallinckrodt is too risky and not worth speculating on
    CNBC Videosyesterday

    Cramer: Mallinckrodt is too risky and not worth speculating on

    Jim Cramer breaks down Mallinckrodt's lawsuit against the federal government and explains why he's bearish on the stock even if it wins.